Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 11:53:32 GMT 2023
by
admin
on
Sat Dec 16 11:53:32 GMT 2023
|
| Protein Sub Type | |
| Sequence Origin | HUMAN |
| Sequence Type | COMPLETE |
| Record UNII |
IBD7PU4RLC
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
IBD7PU4RLC
Created by
admin on Sat Dec 16 11:53:32 GMT 2023 , Edited by admin on Sat Dec 16 11:53:32 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
INHIBITOR -> TARGET | |||
|
WEAK INHIBITOR->TARGET |
|
||
|
WEAK INHIBITOR->TARGET |
IC50
|
||
|
WEAK INHIBITOR->TARGET |
BINDING
IC50
|
||
|
WEAK INHIBITOR->TARGET |
Enzymatic Inhibition
IC50
|
||
|
INHIBITOR -> TARGET |
IC50
|
||
|
WEAK INHIBITOR->TARGET | |||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET | |||
|
NON-INHIBITOR->TARGET |
Mocetinostat (MGCD0103) is a potent HDAC inhibitor but with no activity to HDAC8. Phase 2.
INHIBITOR
NOT CLINICALLY SIGNIFICANT
|
||
|
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
Enzymatic Inhibition
IC50
|
||
|
INHIBITOR -> TARGET |
IN-VIVO
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT | CHEMICAL |
|